Perioperative outcomes in patients who undergo neoadjuvant chemoradiotherapy versus chemotherapy versus up‐front surgery in patients with oesophageal cancer

Abstract

AbstractBackgroundOesophagectomy is the mainstay of curative treatment for oesophageal cancer. The role of neoadjuvant therapy has evolved over time as evidence for its survival benefit comes to hand. Clinician reluctance to offer patients neoadjuvant therapy may be based on the perception that patients receiving treatment before surgery may be exposed to a greater risk of perioperative complications. The aim of this study was to examine short‐term outcomes in patients who undergo neoadjuvant therapy versus up‐front surgery in patients with oesophageal cancer.MethodsThis was a retrospective cohort study of prospectively collated data from 2001 to 2020 of patients undergoing resection for oesophageal cancer. Patients who had neoadjuvant chemoradiotherapy, chemotherapy and up‐front surgery were compared for perioperative morbidity (via the Clavien–Dindo classification), length of stay, unplanned readmission, and 30‐ and 90‐day mortality. Logistic regression was performed to predict perioperative morbidity following surgery.ResultsIn total, 284 patients underwent an oesophagectomy. Most patients received neoadjuvant treatment (41% received chemoradiotherapy (117/284), 33% received chemotherapy (93/284)), and 26% of patients received up‐front surgery (74/284). Patients who received neoadjuvant chemoradiotherapy or up‐front surgery were more likely to have a complication (57%, 67/117 and 57%, 43/74) than patients who received neoadjuvant chemotherapy only (38%, 35/93, P = 0.009). The 30‐ and 90‐day mortality rates were 1.4% (n = 4) and 2.8% (n = 8), respectively, with no difference between the use of neoadjuvant therapy.ConclusionIn this series, we found that patients who received neoadjuvant treatment could undergo oesophagectomy with curative intent with acceptable postoperative morbidity and mortality.